Acriflavine, a HIF-1 inhibitor prevents dimerization of the HIF complex and reduces LSC formation, maintenance, survival and stemness through three mechanisms [17,173,174]: depleting c-Myc at mRNA and protein levels, promoting expression of tumour suppressors (e.g., p57, p19Arf and p16Ink4a) and inhibiting genes that favour LSC stemness (e.g., NANOG, Oct4, Sox9). Here, MYC is linked to neoplasm.